Skip to Content

Myasthenia­ Gravis: Cyclic­ and­ Continuous­ Dosing­ of ­Intravenous­ Efgartigimod

Elena Cortes, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain present in this MEDtalk the results of the ADAPT NXT study. This study analyze the efficacy, safety, and tolerability of 10 mg/kg intravenous efgartigimod administered in a cyclic or continuous dosing regimen.

Elena Cortés Vicente

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top